🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

482 results for “60” Clear

  1. Finlepsin 200 retard, 200 mg, tabletki o przedłużonym uwalnianiu, Orungal, 100 mg, kapsułki, Gemfibrozilo STADA 600 mg comprimidos recubiertos con película EFG, Neurotop retard 300, 300 mg, tabletki o przedłużonym uwalnianiu

    Minoryx Therapeutics S.L.

    Adrenoleukodystrophy

    phase 1 small molecule active

    1 trial

  2. GLPG1972 600 mg oral solution fasted

    Lakefront Biotherapeutics NV

    Osteoarthritis

    phase 1 small molecule completed

    1 trial

  3. HEC116094

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Influenza

    phase 1 small molecule completed

    1 trial

  4. HIV Therapeutic Biologic Mix - HIV GP160 plus BCG Vaccine Mix for percutaneous use

    Lxo Ireland Designated Activity Company

    HIV Infections

    phase 1 mab active

    1 trial

  5. INO-3605

    INOVIO PHARMACEUTICALS, INC.

    Healthy

    phase 1 mab completed

    1 trial

  6. JNJ-56021927

    Janssen Cilag International NV

    Prostatic Neoplasms, Castration-Resistant

    phase 1 small molecule completed

    1 trial

  7. JR8603

    JiaRay Group

    Solid Tumors

    phase 1 small molecule active

    1 trial

  8. LDT600 (Telbivudine)

    Novartis Pharmaceuticals

    Chronic Hepatitis B

    phase 1 small molecule completed

    1 trial

  9. LENVIMA 4 mg hard capsules, volrustomig, Kisplyx 10 mg hard capsules, Kisplyx 4 mg hard capsules, LENVIMA 10 mg hard capsules

    AstraZeneca AB

    Advanced Renal Cell Carcinoma

    phase 1 small molecule active

    1 trial

  10. MRT-6160

    Monte Rosa Therapeutics

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  11. MT-601

    Marker Therapeutics

    Non-Hodgkin Lymphoma, Adult

    phase 1 small molecule active

    1 trial

  12. MT-601 dose 200 million cells

    Marker Therapeutics

    Pancreas Cancer

    phase 1 small molecule active

    1 trial

  13. Molecular imaging with FAPI for diagnosing the CSM4 colorectal cancer subtype

    Disc Medicine

    Colorectal cancer, liver metastases

    phase 1 other active

    1 trial

  14. Multiple-Dose Study on the Bioequivalence of One Tablet of Gliclazide MR 120 mg (S005190) and Two Tablets of Gliclazide MR 60 mg (Diaprel® MR) in Healthy Participants under Fed Conditions.

    The George Institute

    No medical condicion.

    phase 1 other active

    1 trial

  15. Multiple-dose, open-label, laboratory blinded, randomized, 2-period, 2-sequence, crossover, steady-state bioequivalence study comparing the Test Product Naproxen sodium 660 mg modified release tablets with the Reference Product Actromadol 660 mg Modified-Release tablets in healthy adult male and female subjects under fed conditions.

    Laboratorios Tillomed Spain S.L.U

    No medical condition

    phase 1 other active

    1 trial

  16. NBI-6024

    NEUROCRINE BIOSCIENCES INC

    Type 1 Diabetes Mellitus

    phase 1 small molecule completed

    1 trial

  17. NBI-77860

    NEUROCRINE BIOSCIENCES INC

    Congenital Adrenal Hyperplasia

    phase 1 small molecule terminated

    1 trial

  18. NX-1607

    Nurix Therapeutics

    Ovarian Cancer, Epithelial

    phase 1 small molecule active

    1 trial

  19. Neratinib 160 mg

    PUMA BIOTECHNOLOGY, INC.

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  20. Nifedipine 60 MG Extended Release Oral Tablet

    BRIGHT MINDS BIOSCIENCES INC.

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  21. OPB-51602

    Hospital Authority, Hong Kong

    Nasopharyngeal Carcinoma

    phase 1 small molecule terminated

    1 trial

  22. Open-label, non-randomised, single-dose, one sequence, two-period, cross-over study to investigate the effect of inhibition of P-glycoprotein and breast cancer resistance protein transporters by cyclosporine on the pharmacokinetics of CHF6001 in healthy volunteers.

    Chiesi Farmaceutici S.p.A

    Chronic obstructive pulmonary disease

    phase 1 other active

    1 trial

  23. PF-05280602

    CATALYST PHARMACEUTICALS, INC.

    Hemophilia A

    phase 1 mab completed

    1 trial

  24. Phase Ib Dose Finding Study of [177Lu]Lu-NeoB in Combination with RT and TMZ in Newly Diagnosed Glioblastoma and as a Single Agent in Recurrent Glioblastoma

    Novartis Pharmaceuticals

    Glioblastoma

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources